Investigating the effect of doxorubicin drug on the expression of immune checkpoint PD-L1 and related miRNAs in osteosarcoma cancer

Abstract

Osteosarcoma refers to a type of malignant neoplasm growth of bone tissue. The origin of this type of cancer is bone mesenchymal cells, so it is called sarcoma. High expression of PDL-1 by cancer cells is known. Since the effects of antibodies against PD1-PDL-1 are known, alternative treatment methods such as the use of Doxorubicin to suppress a specific gene can be performed. In this study, the aim is to use specific Doxorubicin to express PDL 1 is suppressed and the effect of this simultaneous suppression on the related microRNAs is investigated.

Materials and methods:

First, the two cell lines were cultured. Then Doxorubicin and anti-miR-222 were transfected into the desired cell line. In order to investigate this gene suppression on the rate of growth and proliferation of cancer cells, genes involved in growth, proliferation and metastasis (PDL-1, miR-30a, miR-122, miR-513, miR-570) were investigated by PCR-RT method. After collecting data in Excell software, data organization was done and then data distribution was checked using Prism software and for normal distribution by Test-T test and for data with non-normal distribution by Whitney test. -Mann was used.

Results: In both osteosarcoma cancer cell lines, we observed a significant increase in PDL-1 expression after Doxorubicin treatment. Compared to the control group, our results showed significantly increased expression of micro RNAs such as miR-513, miR-122, miR-34a and miR-570 after adding Doxorubicin. Also, when Doxorubicin and anti-miR-222 were used at the same time, we saw a decrease in viability and an increase in apoptosis of cancer cells.